Trials / Completed
CompletedNCT01128179
Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD
A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanthanum carbonate | 1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks |
| DRUG | Placebo | Matching placebo chewable tablets administered 3 times a day for 12 weeks |
Timeline
- Start date
- 2010-12-06
- Primary completion
- 2012-04-16
- Completion
- 2012-04-16
- First posted
- 2010-05-21
- Last updated
- 2021-06-09
- Results posted
- 2013-05-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01128179. Inclusion in this directory is not an endorsement.